A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

• Participants must have NSCLC with Stage IV or recurrent disease following multimodaltherapy for locally advanced disease.

• Study treatment must be first-line therapy for Stage IV or recurrent disease.

• Participants in all parts of the study must have:

• measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1. (RECIST v1.1)

• an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• a life expectancy of at least 3 months at the time of first dose

Exclusion Criteria:

• Untreated symptomatic central nervous system metastases

• Participants with epidermal growth factor receptor (EGFR)/ALK receptor tyrosinekinase (ALK)/ROS proto-oncogene 1 (ROS1)/neurotrophic tyrosine receptor kinase (NTRK)/MET proto-oncogene (MET)/B-Raf proto-oncogene (BRAF)/RET proto-oncogene (RET)mutations amenable to targeted therapies

• Participants with any known medical condition that, in the investigator's opinion,would increase the risk associated with study participation or study drugadministration or interfere with the interpretation of safety results

Note: Other protocol-defined inclusion/exclusion criteria apply.